Disulfidptosis heterogeneity in breast cancer uncovers PTTG1IP as an actionable therapeutic target  

作　　者：Kun Fang Suxiao Jiang Zhengjie Xu Meng Luo Changsheng Yan 

机构地区：[1]Department of Surgery,Yinchuan Maternal and Child Health Hospital,Yinchuan,Ningxia 750001,China [2]Department of Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150001,China

出　　处：《Genes & Diseases》2025年第1期118-121,共4页基因与疾病(英文)

基　　金：supported by the Ningxia Reproductive Disease Clinical Medical Research Center Project(No.2023LCYX003);Ningxia Hui Autonomous Region Natural Science Foundation Project(2022AAC03748);Ningxia Hui Autonomous Region Natural Science Foundation Project(No.2021AAC03523);Basic research project of Yinchuan Maternal and Child Health Hospital(No.2022NYFYCX05);Yinchuan Science and Technology Innovation Project(No.2023SF25);Basic research project of Yinchuan Maternal and Child Health Hospital(No.2023NYFYCX01)(all China).

摘　　要：Breast cancer(BRCA)is the dominating form of cancer affecting women,with an estimated 2.3 million newly diagnosed cases and 685,000 deaths in 2020.1 An emerging study has proposed a novel metabolism-related regulated cell'death modality called disulfidptosis induced by abnormal_accumulation_of intracellular disulfides in SLC7A11high tumor cells.2 However,research on disulfidptosis remains in its infancy.The study presents for the first time a comprehensive investigation on disulfidptosis in BRCA.

关 键 词：BRCA METABOLISM CANCER 

分 类 号：R737.9[医药卫生—肿瘤]